Avanafil: ingredient and products

Avanafil is the PDE5 inhibitor in Stendra and Spedra. Its rapid-onset evidence is a useful feature, provided “success observed early in a trial” is kept separate from “a reliable personal result after fifteen minutes.”

Key points

• Rapid-onset results concern defined sexual attempts in a study, not a guarantee for every user.
• The earliest statistically significant result is not the same as the typical response.
• Strength-specific instructions and interacting medicines still determine the prescribing context.
• Stendra and Spedra are regional product records for the same ingredient.
• A company listing for another avanafil brand is not a clinical trial of that product.

Read the endpoint behind “fast”

A randomized, double-blind trial assigned 440 men with ED to placebo, avanafil 100 mg or avanafil 200 mg. Following a four-week run-in, treatment lasted eight weeks. The main outcome was each participant’s proportion of attempts achieving an erection sufficient for vaginal penetration within approximately fifteen minutes, with successful completion of intercourse required as well.

The mean participant-level percentage of successful early attempts was 25.9% with 100 mg, 29.1% with 200 mg and 14.9% with placebo. These are averages of attempt proportions. They are not percentages of men guaranteed to respond, nor an overall success rate for attempts made later in the treatment window.

The researchers detected a statistically significant treatment difference as early as ten minutes in the 200 mg group and twelve minutes in the 100 mg group. That finding shows an early effect under the trial’s conditions. It does not make the earliest time the best instruction for every prescribed strength or person. The study also did not compare avanafil directly with sildenafil, tadalafil or vardenafil.

How this fits the product labels

The Stendra US information and Spedra EU information set their own timing, amount and interaction instructions. The US label distinguishes the lower-strength timing from the 100/200 mg context. A person should use the instructions for the supplied product, not turn the trial’s earliest result into a personal waiting-time rule.

Food can alter the timing of peak concentration. Sexual stimulation remains necessary. Avanafil is therefore an option for an erection-response problem, not an automatic erection or a treatment for every cause of reduced desire.

Tolerability can decide the comparison

Headache, flushing and nasal congestion are familiar adverse effects; the rapid-onset study mostly reported mild or moderate events. That does not prove avanafil has fewer side effects than every alternative, because the study’s comparator was placebo.

Strong CYP3A4 inhibitors can markedly raise exposure and are restricted by the labels; moderate inhibitors also affect prescribing instructions. Nitrates are incompatible with avanafil. Blood-pressure medicines, alpha-blockers, alcohol and cardiovascular history can change the assessment. A shorter advertised onset does not create a shorter checklist of interactions.

For an erection lasting four hours, sudden vision or hearing loss, or chest pain, seek urgent care and identify the medicine taken. The safety page explains the shared warning signs.

Stendra, Spedra and the other names

Stendra is documented here through a US labeler record, and Spedra through an EU authorization-holder record. They should not be merged into a single worldwide company or packaging identity. Avana is separately listed by Sunrise Remedies; Super Avana adds dapoxetine and raises a second treatment question.

Sources

3 sources

Checked October 4, 2026.

1. Spedra EU product information — European Medicines Agency
2. Stendra US prescribing information — DailyMed
3. Randomized rapid-onset avanafil trial — Journal of Urology, 2015